Study Title
18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC
Study Details
Description:
A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy monotherapy according to EMA label and national guidelines will be enrolled in this trial. All subjects will undergo a whole body 18F-PD-L1 PET/CT scan before start of nivolumab containing treatment. Patients will continue treatment until disease progression, withdrawal of patient consent or unacceptable toxicity.
Sponsor:
The Netherlands Cancer Institute
Contacts:
Joop de Langen, MDj.d.langen@nki.nl
+3120512 ext 9111
Marianne Mahn, MScm.mahn@nki.nl
+3120512 ext 2974
Government Study Link:
NCT03564197 - Click here to see study onClinicalTrials.gov